Additionally, the growing data on the role of CD123 and the promising results of clinical studies carried out with inhibitors of this molecule (in particular Tagraxofusp, a CD123-directed cytotoxin consisting of the fusion of interleukin-3 with a truncated diphtheria toxin payload) make it a target of choice in the treatment of MPN [143]. Here, IL3 is linked to myeloproliferative neoplasm.